On November 20, Anya Biopharm announced the relocation of its Indian subsidiary’s original R&D laboratory from the incubation center at L.M. College of Pharmacy to a larger, upgraded facility in Ahmedabad, which now serves as a formulation pilot plant. The new facility specializes in producing oral dosage forms such as capsules and tablets, with a batch capacity of up to 10,000 units—sufficient for clinical trial requirements.
The upgraded laboratory is equipped with two new high-performance liquid chromatography systems and other advanced analytical instruments, doubling its efficiency in testing and analysis. Previously, the company relied on outsourcing for manufacturing and some testing tasks, but the new facility significantly enhances efficiency and reduces time delays.
Anya Biopharm’s Indian subsidiary started as a university-based lab, later establishing an 800-square-foot (approximately 22.5 square meters) shared laboratory within the university’s incubation center. Today, it has expanded to a self-owned, 3,000-square-foot (approximately 85 square meters) pilot plant. “This journey reflects our commitment to careful planning and prudent use of R&D funding,” the company stated.
Ahmedabad, a key economic and industrial hub in India and part of the Indian government’s Smart City initiative, offers advanced healthcare infrastructure and flexible regulatory management, fostering the growth of its pharmaceutical industry. Currently, the city hosts over 380 thriving pharmaceutical companies. In Gujarat state, where Ahmedabad is located, pharmaceutical production accounts for one-third of India’s total output, with exports comprising approximately 28% of India’s total pharmaceutical export value.
The establishment of the self-owned pilot plant and laboratory allows Anya Biopharm to accelerate the development of oral peptide formulations and clinical trial materials. The facility resolves scheduling bottlenecks previously encountered at the incubation center, streamlining manufacturing and testing processes for preclinical and clinical trial drugs.
The new pilot plant is capable of producing oral dosage forms like capsules and tablets, handling processes from granulation and tablet compression to packaging and stability testing. These capabilities enable Anya Biopharm to rapidly collaborate with international pharmaceutical companies and drug developers to create customized oral formulations, expand product portfolios, and extend product life cycles.
Anya Biopharm's first commercialized product, ANY002, has completed preclinical and early human trials. It has been licensed to major pharmaceutical companies in regions including Europe, the United States, Canada, Australia, and India, with negotiations ongoing for other markets. Meanwhile, the company’s second product, ANY004, is set to enter early-stage human trials and aims for regulatory approval as a 505(b)(2) new drug.
Both ANY002 and ANY004 focus on GLP-1-based therapies, which are currently in high demand. GLP-1 (glucagon-like peptide-1) stimulates insulin secretion in the gastrointestinal tract, lowering blood sugar levels, and regulates appetite in the central nervous system, promoting satiety. As a result, GLP-1 medications are not only effective for diabetes management but have also become popular as weight-loss treatments.
Emerging research suggests additional applications for GLP-1 in conditions such as non-alcoholic fatty liver disease (NAFLD), Parkinson’s disease, and Alzheimer’s disease, indicating its potential to address a broader range of medical conditions in the near future.
Resource: 奧孟亞印度新實驗室暨先導廠啟動 研發量能大幅倍增
